328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407

Abstract

First-line pembrolizumab (pembro) + paclitaxel and carboplatin (chemo) improved outcomes vs placebo (pbo) + chemo in Chinese patients (pts) with metastatic squamous NSCLC enrolled in the KEYNOTE-407 global and China extension studies, consistent with the global study population. We report long-term outcomes in Chinese pts from these studies.